Osteoporosis, Age-Related Clinical Trial
Official title:
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.
In postmenopausal women, who have increased sympathetic outflow, to test the hypothesis that treatment with low doses of a non-selective β-blocker (propranolol) will increase serum markers of bone formation and reduce markers of bone resorption (Aim 1a); and using increasingly β1-AR (adrenergic receptor) selective blockers (atenolol and nebivolol), to better define the β-adrenergic receptor selectivity (β1 versus β2) in the regulation of bone turnover by sympathetic outflow in humans. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
| Completed |
NCT03512262 -
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
|
Phase 3 | |
| Completed |
NCT04167150 -
Tart Cherry Supplementation and Women's Bone Health Study
|
N/A | |
| Withdrawn |
NCT02091492 -
Teriparatide for Fracture Repair in Humans
|
Phase 3 | |
| Completed |
NCT02732210 -
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
|
||
| Completed |
NCT05197244 -
A Culinary Intervention for Bone Health
|
N/A | |
| Recruiting |
NCT05927623 -
Multifaceted Intervention Using Telehealth to Reduce the Risk of Falls and Fractures in Older Men
|
N/A |